Navigation Links
Curing addiction with cannabis medicines
Date:3/7/2008

Smokers trying to quit in the future could do it with the help of cannabis based medicines, according to research from The University of Nottingham.

Teams of pharmacologists, studying the cannabis-like compounds which exist naturally in our bodies (endocannabinoids), are exploring the potential for medical treatment. This includes treating conditions as diverse as obesity, diabetes, depression and addiction to substances like nicotine.

Scientists have known about endocannabinoids since the mid-1990s. This led to an explosion in the number of researchers looking into the future medical uses of cannabinoids and cannabis compounds.

Dr Steve Alexander, Associate Professor in the School of Biomedical Sciences, focused on a number of these projects in editing the first themed podcast for the British Journal of Pharmacology.

Dr Alexander said: It is clear that there is very realistic potential for cannabinoids as medicines. Scientists are looking at a range of possible applications.

One of these researchers is Professor David Kendall, a cellular pharmacologist at the University: The brain is full of cannabinoid receptors. And so, not surprisingly with diseases like depression and anxiety, theres a great deal of interest in exploiting these receptors and in doing so, developing anti-depressant compounds.

Addiction is a real target researchers like Professor Kendall believe the endocannabinoids could be a crucial link to addictive behaviour: We know that the endocannabinoid system is intimately involved in reward pathways and drug seeking behaviour. So this tends to indicate that that if the link involving endocannabinoids and the reward pathway, using inhibitors, can be interrupted, it could turn down the drive to seek addictive agents like nicotine.

Because cannabinoids have also been shown to bring down blood pressure, it is hoped that related compounds can be used in patients with conditions like hypertension.

Dr Michael Randall, a cardiovascular pharmacologist at the University has looked at how endocannabinoids cause blood vessels to relax. This could have many implications, Dr Randall said. The endocannabinoids appear to lower blood pressure under certain conditions; states of shock for example. If the endocannabinoids are of physiological importance, this could have real therapeutic possibilities.

In terms of getting better medicines the endocannabinoid system has a lot to offer, said Dr Alexander. The range of cannabis-related medicines is currently limited, but by increasing our knowledge in this area we can increase our stock.


'/>"/>

Contact: Dr. Steven Alexander
steve.alexander@nottingham.ac.uk
University of Nottingham
Source:Eurekalert

Related medicine news :

1. Business Leaders, Policy Makers and Advocates Gather to Discuss Strategies for Securing the Nations Economy by Investing in Early Childhood
2. Pharmaceutical Product Commercialization & Governance Best Practices: Securing Talent for Highly-Effective Brand Teams
3. Greenway Experiences Quick Success in the Community EHR Marketplace by Securing Contracts with 10 Community-Based Health Organizations
4. Lessons Learned in Securing Top Talent During University Recruiting
5. Novadaq Resumes Normal Business Operations by Securing ICG for SPY
6. NEWSWEEK Cover: The Hunt for an Addiction Vaccine
7. Aussie neuroscientist tests addiction drug
8. UTMB wins $3.4 million federal grant to study addiction-recovery drugs
9. ARMSRx Tackles the New Rx Addiction -- Pharmacy Benefit Audits
10. DNA (driver of nicotine addiction)
11. Cleveland Addiction Agency and National Association Partner to Help Clergy Counsel the Children of Alcoholics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... AL (PRWEB) , ... September 21, 2017 , ... ... provider with offices serving communities in northern Alabama and Georgia, is embarking on ... cancer prevention by utilizing modern early detection methods. , US Breast Cancer ...
(Date:9/20/2017)... ... September 20, 2017 , ... Reflections ... is now accredited by The Joint Commission for chemical dependency and behavioral health ... certifies U.S. health care organizations that meet the commission’s rigorous standards. Accreditation by ...
(Date:9/20/2017)... ... September 20, 2017 , ... Collins Concrete Coatings announced ... that rely on safety and cleanliness. This unique flooring system uses silver ion ... used for centuries for its antimicrobial properties. Unlike antibiotics, which kill specific microorganisms, ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... providing a voice for people who have kidney disease. The theme “Describe a ... share their stories. Entrants needed to meet only one qualification— to have ...
(Date:9/20/2017)... (PRWEB) , ... September 20, ... ... a software company specializing in medical device compliance and commercialization, has just ... risk management activities. , FDA is more adamant than ever about medical ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... , Sept. 7, 2017  For nearly two decades, New Life Agency ... Assisted Reproduction Insurance industry. Today, New Life Agency announces a powerful three-way ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/6/2017)... , Sept. 6, 2017  Robert G. Szewc, ... Pinnacle Professional Member in recognition of his contributions to ... serves as a Nephrologist at the practice of Kidney ... medicine, kidney care and hypertension solutions. He has worked ... years of career experience, as well as expertise in ...
(Date:9/5/2017)... Colo. , Sept. 5, 2017 Sapheneia ... XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party Vendor ... existing CT scanners and allows compliance with current MITA ... Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically designed ... and alerts of potential radiation doses over a predefined ...
Breaking Medicine Technology: